These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 17566047)
1. Chronic subclinical bowel inflammation may explain increased risk of colorectal cancer in obese people. John BJ; Abulafi AM; Poullis A; Mendall MA Gut; 2007 Jul; 56(7):1034-5. PubMed ID: 17566047 [No Abstract] [Full Text] [Related]
2. Faecal calprotectin: the case for a novel non-invasive way of assessing intestinal inflammation. Gearry R; Barclay M; Florkowski C; George P; Walmsley T N Z Med J; 2005 May; 118(1214):U1444. PubMed ID: 15886739 [No Abstract] [Full Text] [Related]
3. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Itzkowitz SH; Yio X Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G7-17. PubMed ID: 15194558 [TBL] [Abstract][Full Text] [Related]
4. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Silberer H; Küppers B; Mickisch O; Baniewicz W; Drescher M; Traber L; Kempf A; Schmidt-Gayk H Clin Lab; 2005; 51(3-4):117-26. PubMed ID: 15819166 [TBL] [Abstract][Full Text] [Related]
5. [Tracing colorectal carcinoma in patients with inflammatory bowel disease]. de Jong DJ; Nagengast FM Ned Tijdschr Geneeskd; 2007 Dec; 151(50):2758-60. PubMed ID: 18232192 [TBL] [Abstract][Full Text] [Related]
6. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Gisbert JP; McNicholl AG Dig Liver Dis; 2009 Jan; 41(1):56-66. PubMed ID: 18602356 [TBL] [Abstract][Full Text] [Related]
7. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. Fagerberg UL; Lööf L; Lindholm J; Hansson LO; Finkel Y J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):414-20. PubMed ID: 18030206 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. von Roon AC; Karamountzos L; Purkayastha S; Reese GE; Darzi AW; Teare JP; Paraskeva P; Tekkis PP Am J Gastroenterol; 2007 Apr; 102(4):803-13. PubMed ID: 17324124 [TBL] [Abstract][Full Text] [Related]
9. [Epidemiology and natural history of chronic inflammatory bowel disease]. Lerebours E; Savoye G; Guedon C Gastroenterol Clin Biol; 2003 Mar; 27(3 Suppl):S76-80. PubMed ID: 12704299 [No Abstract] [Full Text] [Related]
10. Calprotectin and IBD. Lemann M; Mary JY Gut; 2005 Sep; 54(9):1349-50; author reply 1350. PubMed ID: 16099812 [No Abstract] [Full Text] [Related]
11. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Schröder O; Naumann M; Shastri Y; Povse N; Stein J Aliment Pharmacol Ther; 2007 Oct; 26(7):1035-42. PubMed ID: 17877510 [TBL] [Abstract][Full Text] [Related]
12. [Faecal inflammatory markers in nutrition and digestive diseases in children]. Kapel N Arch Pediatr; 2004 May; 11(5):403-5. PubMed ID: 15135420 [No Abstract] [Full Text] [Related]
14. Role of fecal calprotectin test in the work-up of IBS patients. Delgado-Aros S; Cremonini F Gastroenterology; 2003 Apr; 124(4):1164-5. PubMed ID: 12671919 [No Abstract] [Full Text] [Related]
15. Endoscopy/surveillance in inflammatory bowel disease. Ahmadi AA; Polyak S Surg Clin North Am; 2007 Jun; 87(3):743-62. PubMed ID: 17560423 [TBL] [Abstract][Full Text] [Related]
17. Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study. Shastri YM; Povse N; Schröder O; Stein J Clin Lab; 2008; 54(9-10):389-90. PubMed ID: 19097497 [No Abstract] [Full Text] [Related]
18. The changing face of colorectal cancer in inflammatory bowel disease: progress at last! Rubin DT Gastroenterology; 2006 Apr; 130(4):1350-2. PubMed ID: 16618426 [No Abstract] [Full Text] [Related]